(0) items in cart / view cart / checkout  
 
  Chemicals
  Company Profiles
  Country Analyses
  Electronics
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
 
Home > Pharmaceuticals & Biotechnology >  Ethical Pharmaceuticals
 
 Ethical Pharmaceuticals Market Research Reports
Title

To order sections of the reports, contact Client Services.

Price
 1  2  3  4  5  6  7  8  9  10  Next »
Insulin- Global

This package contains 63 insulin market analyses from the following countries: Austria, Belgium, Bulgaria, Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Moldova, the Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Ukraine, the United Kingdom, Armenia, Azerbaijan, China, Georgia, India, Indonesia, Iran, Japan, Jordan, Kazakhstan, Kyrgyzstan, Malaysia, Oman, Pakistan, Singapore, South Korea, Sri Lanka, Thailand, Turkey, Canada, Chile, Colombia, Ecuador, Mexico, Panama, Peru, the United States and Uruguay. The insulin market analyses give an overview of the actual situation, trends and future outlook of the insulin markets in different countries....

 

$26661.00
       
Vaccines - Global

This package contains 63 vaccine market analyses from the following countries: Austria, Belgium, Bulgaria, Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Macedonia, Moldova, the Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Ukraine, the United Kingdom, Australia,Canada, Chile, Colombia, Ecuador, Eritrea, Mexico, Panama, Peru, United States, Uruguay, Armenia, Azerbaijan, China, Georgia, India, Indonesia, Iran, Japan, Jordan, Kazakhstan, Kyrgyzstan, Malaysia, Oman, Pakistan, Singapore, South Korea, Sri Lanka, Thailand, Turkey, Ethiopia, Ghana, Morocco and Nigeria. The vaccine market analyses give an overview of the actual situation, trends and future outlook of the vaccine markets in different countries.

 

$26661.00
       
Analytical Tool Antibodies and Peptides in Oncology

Analytical Tool Antibodies and Peptides in Oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future....

 

$22312.50
       
Analytical Tool - Hematological Cancers

Analytical Tool Hematological Cancers offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future....

 

$22312.50
       
Analytical Tool - Cancer Immunotherapy

Analytical Tool- Cancer Immunotherapy offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in immunotherapy drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future....

 

$20437.50
       
Analytical Tool - Protein Kinase Inhibitors in Oncology

Analytical Tool - Protein Kinase Inhibitors in Oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs) for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future....

 

$16683.75
       
Hepatitis B Drug Market Forecasts by Country

This model contains ten-year commercial forecasts for hepatitis B drug sales by class, molecule and brand for the US, Japan, France, Germany, Italy, Spain, UK and Turkey.

Reasons to Purchase

  • Understand the changing market dynamics of hepatitis B drugs, and success factors for leading brands....

 

$15200.00
       
HIV Antiretrovirals Market Forecasts

In 2009, HIV antiretrovirals sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10....


 

$15200.00
       
Cytotoxic Therapies: Drug Launches in Rare Indications to Offset Sales Decline

Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%....


 

$15200.00
       
Antihormonal Cancer Therapies: Leading Brands Strive to Minimize Generic Sales Erosion

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers....


 

$15200.00
       
Gastric Cancer

Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease....


 

$15200.00
       
Spondyloarthropathies: Disease Perception Limits Market

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arthritis of the spine and sacroiliac joints....


 

$15200.00
       
Commercial Insight: Cardiovascular and Metabolic Market Overview
Innovative Development Pipeline Provides Limited Growth
As Primary Care Markets Become Generic


Introduction

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2018. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0....


 

$15200.00
       
Pharmaceutical Licensing Overview: Risk-Aversion Breeds Creativity as Externalization Intensifies

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic....


 

$15200.00
       
Oncology Drug Pathway Analyzer (Premium Version)

Get instant, interactive modeling on almost 3,000 cancer drugs and affected signaling pathways across close to 90 different cancer types. Drug targets and their pathways are the critical link between drugs and their role in the treatment of cancer....

 

$14850.00
       
Analytical Tool - Cancer Therapeutic Antibodies

Analytical Tool - Cancer Therapeutic Antibodies offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future....

 

$14808.75
       
The 2011 Top Ten World's Leading Pharmaceutical Companies

A thought-provoking report on performance, capabilities, goals and strategies of the major competitors in the worldwide pharmaceutical market. The report is designed to provide the pharmaceutical industry executives with strategically significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs....

 

$13200.00
       
Triple Analysis: Lymphoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology....

 

$12937.50
       
    1  2  3  4  5  6  7  8  9  10   Next »
 
VPGMarketResearch.com © Copyright 2010. all rights reserved. Web Design by Spida Design  
  Close  X